Telehealth and Controlled Substances: Navigating the Post-PHE Compliance Labyrinth in 2025-2026

2026-08-29

As the healthcare landscape moves beyond the Public Health Emergency, telehealth providers prescribing controlled substances face a complex and rapidly evolving regulatory environment. This definitive guide unpacks the critical DEA requirements, state-specific variations, and enforcement trends that will shape compliance for 2025-2026, offering actionable insights for safeguarding your practice.

The COVID-19 Public Health Emergency (PHE) dramatically expanded the scope of telehealth, particularly concerning the prescription of controlled substances. While these flexibilities significantly enhanced access to care, they also ushered in a new era of regulatory scrutiny. As we look to 2025-2026, healthcare businesses engaged in telehealth prescribing of controlled substances are confronting a compliance labyrinth, characterized by evolving federal mandates, disparate state requirements, and an aggressive enforcement climate. Navigating this complexity demands a sophisticated understanding of both federal DEA regulations and the intricate patchwork of state laws. Failure to adapt can result in severe penalties, as recent enforcement actions vividly illustrate.

> For more on this topic, see our analysis: [Navigating the Labyrinth: Controlled Substance Prescribing via Telehealth in 2025-2026](/blog/telehealth-controlled-substance-prescribing-2025-2026-mt79wwae).

The Evolving Regulatory Landscape: A Federal Perspective

The core of controlled substance prescribing via telehealth remains anchored to the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (21 U.S.C. § 802(54)). This federal law generally requires an in-person medical evaluation *before* a controlled substance can be prescribed via the internet. The PHE waivers temporarily suspended this requirement, allowing for telehealth-only prescriptions under specific conditions. However, those waivers have expired, and the DEA has been working on permanent rules, creating a period of uncertainty and proposed guidelines.

DEA's Post-PHE Stance: Proposed Permanent Rules

The DEA's proposed rules, initially introduced in March 2023 and subject to subsequent extensions and modifications, are designed to establish permanent guardrails for telehealth prescribing of controlled substances. While the final rules are still anticipated, the proposed framework provides critical insight into the likely direction of federal policy:

Initial In-Person Exam for Schedule II-V: For initial prescriptions of Schedule II through V controlled substances, the proposed rules generally revert to the Ryan Haight Act's in-person examination requirement. This means a patient must have an in-person medical evaluation with the prescribing practitioner, or another practitioner working in the *same DEA-registered practice*, prior to receiving a controlled substance prescription via telehealth.
Telehealth-Only Exception for Non-Narcotic Schedule III-V: A limited exception is proposed for *non-narcotic* Schedule III-V controlled substances. In these cases, an initial telehealth encounter *without a prior in-person exam* may be permissible, provided it meets specific criteria, including a comprehensive medical evaluation and follow-up care arrangements. However, such a prescription would be limited to a 30-day supply, after which an in-person examination would be required for subsequent refills.
Exceptions for Bona Fide Medical Emergencies: The proposed rules maintain exceptions for certain emergencies, though these are narrowly defined and require strict adherence to reporting and follow-up protocols.

These proposals underscore the DEA's cautious approach to remote prescribing of controlled substances, prioritizing patient safety and diversion prevention. The regulatory shift from the PHE's expansive flexibilities back to a more restrictive framework will necessitate significant operational adjustments for many telehealth providers.

Recent DEA Enforcement & Scheduling Actions: A Wake-Up Call

The DEA is not merely proposing new rules; it is actively enforcing existing ones and dynamically adapting to emerging threats. Recent actions serve as potent reminders of the agency's vigilance:

The Walmart Settlement (2024): A $50 million settlement with Walmart Inc. over allegations of illegally filling thousands of invalid opioid prescriptions highlights the critical importance of pharmacist oversight and red flag identification. While Walmart was the target, the enforcement action sends a clear message to prescribers: your prescriptions are subject to scrutiny by pharmacists, who are obligated to refuse to fill invalid or suspicious orders. Telehealth prescribers must ensure their prescriptions are not only clinically appropriate but also robustly documented to withstand such scrutiny.
Cipepofol (Cypsedo) Scheduling (2026): The DEA's interim final rule placing cipepofol (Cypsedo) in Schedule IV of the CSA demonstrates the agency's ongoing process of classifying new substances. For practices utilizing or considering newly approved medications, continuous monitoring of DEA scheduling actions (e.g., via the Federal Register) is paramount. Improper handling or prescribing of a newly scheduled substance, even inadvertently, constitutes a compliance violation.
Temporary Scheduling of Synthetic Opioids (2026-2028): The temporary placement of four synthetic opioids (e.g., 5,6-dichloro brorphine) into Schedule I underscores the DEA's rapid response capabilities to public health threats. While these are illicit substances, this action reinforces the dynamic nature of controlled substance regulation and the need for robust internal drug diversion prevention programs and toxicology testing awareness.

These actions, combined with the HHS OIG and DOJ's coordinated, escalated healthcare fraud enforcement, signal an increasingly aggressive stance against non-compliance across the entire healthcare ecosystem. The DOJ's National Fraud Enforcement Division (NFED) is deploying significant resources and

Telehealth and Controlled Substances: Navigating the Post-PHE Compliance Labyrinth in 2025-2026

The Evolving Regulatory Landscape: A Federal Perspective

DEA's Post-PHE Stance: Proposed Permanent Rules

Recent DEA Enforcement & Scheduling Actions: A Wake-Up Call

Further Reading